Medivir - New data for Simeprevir Will be Presented at EASL's International Liver Congress™ 2017

Stockholm, April 06, 2017 /PRNewswire/ --

Medivir AB (Nasdaq Stockholm: MVIR)today informs that new clinical data for simeprevir, an NS3/4A protease inhibitor for the treatment of hepatitis C virus infection, will be presented by our partner Janssen Sciences Ireland UC (Janssen) in conjunction with The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April.

A total of four presentations will be made, including one oral presentation. The presentations will cover preclinical and clinical data on the triple combination of simeprevir, odalasvir and AL-335, as well as data on the efficacy, safety and tolerability of simeprevir used as a component of various combination therapies in a number of different adult patient populations.

Data presented at the International Liver Congress™ 2017 include:

Oral Presentation:

Abstract PS-153

Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis.
Authors: Ed Gane, Catherine Stedman, Matthew McClure, David Apelian, Chris Westland, Jennifer Vuong, Megha Patel, Thomas Kakuda, Sushmita Chanda, Lawrence Blatt, Leo Beigelman, David Smith, John Fry

Poster Presentations:

Abstract FRI-276

In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir.
Authors: Leen Vijgen, Bart Fevery, Andreas Jekle, Kenneth Shaw, Hua Tan, Oliver Lenz, Julian Symons, Sandra De Meyer

Abstract THU-281

Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies.
Authors: Fiona Marra, Christoph Höner zu Siederdissen, Saye Khoo, Markus Cornberg, Michael Schlag, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer, David Back

Abstract FRI-249

Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy.
Authors: John Dillon, Stefan Mauss, Catherine Nalpas, Ceyhun Bicer, Michael Schlag, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer

Details of all presentations for The International Liver Congress™ 2017 are available at: http://www.easl.eu/.

For further information, please contact:

Richard Bethell,
CSO Medivir AB,
Mobile +46 (0)72-704-3211

Ola Burmark,
CFO Medivir AB,
Mobile: +46 (0)725-480-580

About Medivir

Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.

 This information was brought to you by Cision http://news.cision.com
http://news.cision.com/medivir/r/new-data-for-simeprevir-will-be-presented-at-easl-s-international-liver-congress--2017,c2233890

The following files are available for download:

SOURCE Medivir